Contrasting Amphastar Pharmaceuticals (AMPH) and Akorn (AKRX)
Amphastar Pharmaceuticals (NASDAQ: AMPH) and Akorn (NASDAQ:AKRX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.
Earnings and Valuation
This table compares Amphastar Pharmaceuticals and Akorn’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Amphastar Pharmaceuticals||$255.16 million||3.34||$10.53 million||N/A||N/A|
|Akorn||$1.12 billion||3.72||$184.24 million||$0.99||33.55|
Akorn has higher revenue and earnings than Amphastar Pharmaceuticals.
Insider and Institutional Ownership
44.0% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 68.7% of Akorn shares are held by institutional investors. 11.1% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 28.2% of Akorn shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of current ratings for Amphastar Pharmaceuticals and Akorn, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Amphastar Pharmaceuticals presently has a consensus target price of $20.33, suggesting a potential upside of 9.61%. Akorn has a consensus target price of $30.14, suggesting a potential downside of 9.24%. Given Amphastar Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Amphastar Pharmaceuticals is more favorable than Akorn.
This table compares Amphastar Pharmaceuticals and Akorn’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Amphastar Pharmaceuticals has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, Akorn has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.
Akorn beats Amphastar Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.
Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals in a range of dosage forms, including sterile ophthalmics, injectables and inhalants and non-sterile oral liquids, topicals and nasal sprays and otics. The Consumer Health segment consists of branded and private-label OTC products and animal health products dispensed by veterinary professionals. Its branded and private-label OTC products are focused on ophthalmics, including a dry eye treatment TheraTears Therapy for Your Eyes.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.